US8038994B2
(en)
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
ES2329437T3
(es)
*
|
1999-06-25 |
2009-11-26 |
Genentech, Inc. |
Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
|
DK2803367T3
(en)
*
|
1999-06-25 |
2018-04-16 |
Immunogen Inc |
Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
|
US6825333B1
(en)
|
1999-08-20 |
2004-11-30 |
Chiron Corporation |
EGFH2 genes and gene products
|
US6627196B1
(en)
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
EP2266607A3
(en)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
ES2331646T3
(es)
|
2000-05-19 |
2010-01-12 |
Genentech, Inc. |
Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
|
EP1228766A1
(en)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
AU2002358246B2
(en)
*
|
2001-10-26 |
2008-02-28 |
Oncoquest Pharmaceuticals Inc. |
Combination therapy for treating disease
|
WO2003087338A2
(en)
*
|
2002-04-11 |
2003-10-23 |
Amgen, Inc. |
Her-2 receptor tyrosine kinase molecules and uses thereof
|
ITTO20020340A1
(it)
*
|
2002-04-19 |
2003-10-20 |
Biother Di Contardi Gabriella |
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
|
AU2003237367A1
(en)
|
2002-06-03 |
2003-12-19 |
Chiron Corporation |
Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
|
AT413486B
(de)
*
|
2002-07-03 |
2006-03-15 |
Igeneon Krebs Immuntherapie |
Verwendung eines antikörpers gerichtet gegen lewis-antigene
|
NO340576B1
(no)
*
|
2002-07-11 |
2017-05-15 |
Hoffmann La Roche |
Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
|
PL214010B1
(pl)
*
|
2002-07-15 |
2013-06-28 |
Genentech Inc |
Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
|
KR20050038005A
(ko)
|
2002-07-18 |
2005-04-25 |
헬릭스 바이오파마 코포레이션 |
암세포 성장의 저해를 위한 우레아제의 사용
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
US7264800B2
(en)
|
2002-07-18 |
2007-09-04 |
Helix Biopharma Corporation |
Method and composition for inhibiting cancer cell growth
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
AU2003248982B2
(en)
*
|
2002-08-01 |
2009-12-10 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
JP4790413B2
(ja)
*
|
2002-10-08 |
2011-10-12 |
イミューノメディクス、インコーポレイテッド |
抗体療法
|
EP1572242B1
(en)
|
2002-12-13 |
2014-04-16 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
JP2007517767A
(ja)
*
|
2003-03-11 |
2007-07-05 |
ダナ ファーバー キャンサー インスティテュート |
ウイルスの病原性の阻害方法
|
ES2368737T3
(es)
*
|
2003-04-23 |
2011-11-21 |
Medarex, Inc. |
Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
AT500651B9
(de)
*
|
2003-05-27 |
2010-04-15 |
Altropus Gmbh |
Aktiv immunisierender antikörper
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
AU2004242614B2
(en)
|
2003-05-30 |
2011-09-22 |
Merus N.V. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
AU2004265253B2
(en)
|
2003-07-28 |
2011-09-01 |
Genentech, Inc. |
Reducing protein A leaching during protein A affinity chromatography
|
US20070104714A1
(en)
*
|
2003-08-29 |
2007-05-10 |
Cedars-Sinai Medical Center |
Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis
|
WO2005028498A2
(en)
*
|
2003-09-18 |
2005-03-31 |
Raven Biotechnologies, Inc. |
Kid3 and kid3 antibodies that bind thereto
|
BRPI0416987A
(pt)
*
|
2003-11-28 |
2007-08-21 |
Mitra Medical Technology Ab |
direcionamento de antìgenos de erb
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
KR20150140417A
(ko)
|
2004-07-22 |
2015-12-15 |
제넨테크, 인크. |
Her2 항체 조성물
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
ZA200704796B
(en)
*
|
2004-12-07 |
2008-11-26 |
Genentech Inc |
Selecting patients for therapy with a HER inhibitor
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
AR053272A1
(es)
*
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
KR101164820B1
(ko)
|
2005-09-22 |
2012-07-12 |
삼성전자주식회사 |
디스플레이장치
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1962584A2
(en)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
CA2652945C
(en)
|
2006-05-30 |
2015-06-02 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
JP2009539836A
(ja)
*
|
2006-06-05 |
2009-11-19 |
ジェネンテック・インコーポレーテッド |
EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長
|
AR062419A1
(es)
|
2006-08-21 |
2008-11-05 |
Hoffmann La Roche |
Terapia tumoral con un anticuerpo anti- vegf
|
WO2008031531A1
(en)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
CN101594883B
(zh)
*
|
2006-10-12 |
2018-04-10 |
中外制药株式会社 |
使用抗ereg抗体的癌症的诊断和治疗
|
CA2667019C
(en)
|
2006-10-27 |
2016-03-29 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
NZ578824A
(en)
*
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
US20100254996A1
(en)
*
|
2007-06-18 |
2010-10-07 |
Medimmune, Llc |
Synergistic treatment of cells that express epha2 and erbb2
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
PL2840090T3
(pl)
|
2007-10-30 |
2018-07-31 |
Genentech, Inc. |
Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
|
BRPI0819656A2
(pt)
*
|
2007-11-27 |
2015-06-23 |
Ablynx Nv |
Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
|
ES2437595T3
(es)
|
2007-12-20 |
2014-01-13 |
Novartis Ag |
Derivados de tiazol usados como inhibidores de la PI 3 quinasa
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US20110189206A1
(en)
|
2008-01-03 |
2011-08-04 |
Barbas Iii Carlos F |
Antibody Targeting Through a Modular Recognition Domain
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
PL2247620T3
(pl)
|
2008-01-31 |
2017-08-31 |
Genentech, Inc. |
Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
|
ES2544682T3
(es)
*
|
2008-03-14 |
2015-09-02 |
Genentech, Inc. |
Variaciones genéticas asociadas con la resistencia a fármacos
|
TWI675668B
(zh)
*
|
2008-03-18 |
2019-11-01 |
美商建南德克公司 |
抗her2抗體-藥物結合物及化療劑之組合及使用方法
|
KR20120127543A
(ko)
|
2008-05-23 |
2012-11-21 |
시와 코퍼레이션 |
재생을 촉진하는 방법, 조성물 및 장치
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
EP2334323A2
(en)
|
2008-09-10 |
2011-06-22 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
EP3470087A1
(en)
|
2009-02-13 |
2019-04-17 |
Immunomedics, Inc. |
Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
KR20110124368A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항―erbb―2/항―c―met 항체
|
JP5808052B2
(ja)
|
2009-05-29 |
2015-11-10 |
中外製薬株式会社 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
PT2464725T
(pt)
|
2009-08-11 |
2020-05-21 |
Hoffmann La Roche |
Produção de proteínas em meios de cultura celular isentos de glutamina
|
SG178419A1
(en)
*
|
2009-08-15 |
2012-04-27 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
WO2011028753A1
(en)
|
2009-09-01 |
2011-03-10 |
Genentech, Inc. |
Enhanced protein purification through a modified protein a elution
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
US8658175B2
(en)
*
|
2009-10-28 |
2014-02-25 |
Abbvie Biotherapeutics Inc. |
Anti-EGFR antibodies and their uses
|
EP2496601B1
(en)
|
2009-11-05 |
2017-06-07 |
F. Hoffmann-La Roche AG |
Methods and composition for secretion of heterologous polypeptides
|
CN105999263B
(zh)
|
2009-11-13 |
2021-06-29 |
第一三共欧洲有限公司 |
用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
|
US10584181B2
(en)
|
2009-12-04 |
2020-03-10 |
Genentech, Inc. |
Methods of making and using multispecific antibody panels and antibody analog panels
|
US9115200B2
(en)
*
|
2010-02-04 |
2015-08-25 |
Toray Industries, Inc. |
Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
|
MX2012008958A
(es)
*
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
ES2722201T3
(es)
|
2010-03-22 |
2019-08-08 |
Hoffmann La Roche |
Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
JP6082344B2
(ja)
|
2010-05-27 |
2017-02-15 |
ゲンマブ エー/エス |
Her2エピトープに対するモノクローナル抗体
|
CN103154035B
(zh)
|
2010-05-27 |
2017-05-10 |
根马布股份公司 |
针对her2的单克隆抗体
|
ES2599412T3
(es)
|
2010-05-28 |
2017-02-01 |
F. Hoffmann-La Roche Ag |
Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
WO2011156328A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
MY184736A
(en)
|
2010-06-24 |
2021-04-20 |
Genentech Inc |
Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
US8721571B2
(en)
|
2010-11-22 |
2014-05-13 |
Siwa Corporation |
Selective removal of cells having accumulated agents
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
MX357821B
(es)
|
2010-12-21 |
2018-07-25 |
Hoffmann La Roche |
Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JP6162044B2
(ja)
|
2010-12-23 |
2017-07-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
結合剤
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
WO2012122378A2
(en)
|
2011-03-08 |
2012-09-13 |
The Trustees Of The University Of Pennsylvania |
Antibody-like proteins for therapeutic and diagnostic use
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー/エス |
Her2およびcd3に対する二重特異性抗体
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
LT2766040T
(lt)
|
2011-10-14 |
2019-08-12 |
F. Hoffmann-La Roche Ag |
Pertuzumabas, trastuzumabas, docetakselis ir karboplatina, skirti ankstyvos stadijos krūties vėžiui gydyti
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
CN104093743B
(zh)
|
2011-11-23 |
2018-04-24 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
WO2013081645A2
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
BR112014015101A8
(pt)
|
2011-12-22 |
2021-06-08 |
Genentech Inc |
métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
AU2013214254B2
(en)
|
2012-01-31 |
2016-04-21 |
Novartis Ag |
Method of treating cancer
|
EP2638916A1
(en)
|
2012-03-16 |
2013-09-18 |
Covagen AG |
Novel binding molecules with antitumoral activity
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
CN114163530A
(zh)
|
2012-04-20 |
2022-03-11 |
美勒斯公司 |
用于产生免疫球蛋白样分子的方法和手段
|
KR101505157B1
(ko)
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
KR20150009540A
(ko)
|
2012-05-16 |
2015-01-26 |
노파르티스 아게 |
Pi-3 키나제 억제제에 대한 투여 요법
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
WO2014108858A1
(en)
|
2013-01-10 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Fatty acid synthase inhibitors
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
CN104628846B
(zh)
|
2013-11-06 |
2019-12-06 |
三生国健药业(上海)股份有限公司 |
重组蛋白质的纯化方法
|
RU2656161C1
(ru)
|
2013-11-19 |
2018-05-31 |
Ремеджен, Лтд. |
Анти-неr2 антитело и его конъюгат
|
CA2931356A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
CN105979947A
(zh)
|
2013-12-06 |
2016-09-28 |
诺华股份有限公司 |
α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
|
KR102362920B1
(ko)
|
2014-01-31 |
2022-02-14 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
WO2015128837A1
(en)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
US10160812B2
(en)
|
2014-04-11 |
2018-12-25 |
Medimmune, Llc |
Bispecific HER2 antibodies
|
CN107108724A
(zh)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
半胱氨酸改造抗体和缀合物
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
US10358502B2
(en)
|
2014-12-18 |
2019-07-23 |
Siwa Corporation |
Product and method for treating sarcopenia
|
US9993535B2
(en)
|
2014-12-18 |
2018-06-12 |
Siwa Corporation |
Method and composition for treating sarcopenia
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
AU2016262168B2
(en)
*
|
2015-05-13 |
2022-06-23 |
Zymeworks Bc Inc. |
Antigen-binding constructs targeting HER2
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
RU2766209C2
(ru)
*
|
2015-10-13 |
2022-02-09 |
Сива Корпорейшн |
Антитела к age и способы их применения
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
WO2017093942A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
CN105646704B
(zh)
*
|
2015-12-28 |
2019-11-15 |
广西医科大学 |
抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
|
JP6722293B2
(ja)
|
2016-02-19 |
2020-07-15 |
シワ コーポレーション |
終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物
|
CN109310754A
(zh)
*
|
2016-03-15 |
2019-02-05 |
梅里麦克制药股份有限公司 |
使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
|
CA3057829A1
(en)
|
2016-04-15 |
2017-10-19 |
Siwa Corporation |
Anti-age antibodies for treating neurodegenerative disorders
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
EP3455260B1
(en)
*
|
2016-05-12 |
2022-07-06 |
Agency for Science, Technology and Research |
Anti-erbb-2 antibodies and uses thereof
|
JP2019518763A
(ja)
|
2016-06-23 |
2019-07-04 |
シワ コーポレーション |
様々な疾患及び障害の治療において使用するためのワクチン
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
JPWO2018066626A1
(ja)
|
2016-10-07 |
2019-07-18 |
第一三共株式会社 |
抗her2抗体−薬物コンジュゲート投与による耐性癌の治療
|
CN110049779A
(zh)
|
2016-12-12 |
2019-07-23 |
第一三共株式会社 |
抗体-药物缀合物和免疫检查点抑制剂的组合
|
US10961321B1
(en)
|
2017-01-06 |
2021-03-30 |
Siwa Corporation |
Methods and compositions for treating pain associated with inflammation
|
US10995151B1
(en)
|
2017-01-06 |
2021-05-04 |
Siwa Corporation |
Methods and compositions for treating disease-related cachexia
|
CN110709419B
(zh)
*
|
2017-01-06 |
2023-11-28 |
博奥信生物技术(南京)有限公司 |
Erbb2抗体及其用途
|
US10925937B1
(en)
|
2017-01-06 |
2021-02-23 |
Siwa Corporation |
Vaccines for use in treating juvenile disorders associated with inflammation
|
US10858449B1
(en)
|
2017-01-06 |
2020-12-08 |
Siwa Corporation |
Methods and compositions for treating osteoarthritis
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
CN116531511A
(zh)
|
2017-03-02 |
2023-08-04 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
TW201834649A
(zh)
|
2017-03-02 |
2018-10-01 |
新加坡商亞獅康私人有限公司 |
癌症療法
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
BR112019021471A2
(pt)
|
2017-04-13 |
2020-05-12 |
Siwa Corporation |
Anticorpo monoclonal humanizado de produto final da glicação avançada
|
WO2018222135A1
(en)
|
2017-06-02 |
2018-12-06 |
Aslan Pharmaceuticals Pte Ltd |
Cancer therapy
|
CN107417791B
(zh)
*
|
2017-08-17 |
2020-09-22 |
合肥瀚科迈博生物技术有限公司 |
抗人ErbB2双特异性抗体、其制备方法及用途
|
BR112020003474A2
(pt)
|
2017-08-23 |
2020-10-20 |
Daiichi Sankyo Company, Limited |
composição farmacêutica, e, método para produzir uma composição farmacêutica
|
KR20200041993A
(ko)
|
2017-08-31 |
2020-04-22 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
IL272964B2
(en)
|
2017-08-31 |
2024-02-01 |
Daiichi Sankyo Co Ltd |
Production method for antibody-drug conjugates
|
CN107789631B
(zh)
*
|
2017-11-03 |
2021-03-16 |
合肥瀚科迈博生物技术有限公司 |
抗人ErbB2双表位抗体-药物偶联物及其应用
|
MX2020006155A
(es)
|
2017-12-12 |
2020-08-13 |
Macrogenics Inc |
Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
|
US11518801B1
(en)
|
2017-12-22 |
2022-12-06 |
Siwa Corporation |
Methods and compositions for treating diabetes and diabetic complications
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
EP3560945A1
(en)
|
2018-04-27 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Methods for purification of polypeptides using polysorbates
|
BR112020024061A2
(pt)
|
2018-05-28 |
2021-02-17 |
Daiichi Sankyo Company, Limited |
agente terapêutico para câncer com her2 mutado
|
SG11202100580UA
(en)
|
2018-07-23 |
2021-02-25 |
Trevi Therapeutics Inc |
Treatment of chronic cough, breathlessness and dyspnea
|
KR20210038904A
(ko)
|
2018-07-25 |
2021-04-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘쥬게이트의 효과적인 제조 방법
|
KR20210040059A
(ko)
|
2018-07-27 |
2021-04-12 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 약물 부위를 인식하는 단백질
|
CA3108044A1
(en)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
JP7458981B2
(ja)
|
2018-08-06 |
2024-04-01 |
第一三共株式会社 |
抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
|
WO2020040245A1
(ja)
|
2018-08-23 |
2020-02-27 |
第一三共株式会社 |
抗体薬物複合体の感受性マーカー
|
JP2022502039A
(ja)
|
2018-09-25 |
2022-01-11 |
エイビーエスシーアイ・エルエルシー |
タンパク質精製方法
|
WO2020084503A1
(en)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
A composition comprising antibody with reduced level of basic variants thereof
|
SG11202106248XA
(en)
|
2018-12-11 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate with parp inhibitor
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
|
JP2022523100A
(ja)
|
2019-02-01 |
2022-04-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ベランタマブマフォドチンおよび抗ox40抗体を含むがんの併用治療ならびにその使用および方法
|
MX2021012032A
(es)
|
2019-04-01 |
2021-11-03 |
Genentech Inc |
Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
|
CN112007169B
(zh)
*
|
2019-05-30 |
2022-03-08 |
湖南大学 |
一种核酸适配体药物偶联物及其制备方法和用途
|
CN110205302B
(zh)
*
|
2019-06-24 |
2021-03-23 |
扬州大学 |
一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
|
KR20220026585A
(ko)
|
2019-06-26 |
2022-03-04 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Il1rap 결합 단백질
|
CN110551214A
(zh)
*
|
2019-08-27 |
2019-12-10 |
杨澜 |
一种人源化抗Periostin单克隆抗体、及其制备方法和应用
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
JP2023542065A
(ja)
|
2020-06-24 |
2023-10-05 |
アストラゼネカ ユーケー リミテッド |
抗体-薬物複合物及びcdk9阻害剤の組み合わせ
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
EP4171651A1
(en)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and atm inhibitor
|
CN116635082A
(zh)
|
2020-06-24 |
2023-08-22 |
阿斯利康(英国)有限公司 |
抗体-药物缀合物和atr抑制剂的组合
|
US20230293714A1
(en)
|
2020-07-20 |
2023-09-21 |
Daiichi Sankyo Company, Limited |
Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
|
BR112023006337A2
(pt)
|
2020-10-09 |
2023-05-09 |
Astrazeneca Uk Ltd |
Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
|
TW202227140A
(zh)
|
2020-11-11 |
2022-07-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物及抗SIRPα抗體之組合
|
AU2022401024A1
(en)
|
2021-11-30 |
2024-05-16 |
Daiichi Sankyo Company, Limited |
Protease-cleavable masked antibodies
|
WO2023126822A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
WO2023218378A1
(en)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
CN117224689B
(zh)
*
|
2023-11-16 |
2024-02-23 |
上海复宏汉霖生物技术股份有限公司 |
联合抗her2抗体和化疗剂治疗胃癌的用途
|